Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

867

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Ad26.COV2.S
BIOLOGICAL: BNT162b2
BIOLOGICAL: mRNA-1273
BIOLOGICAL: mRNA-1273.211
BIOLOGICAL: mRNA-1273.222
BIOLOGICAL: SARS-CoV-2 rS/M1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)